STUART, Fla.– Cognigenics, Inc., a leader in innovative RNA-based gene therapies targeting memory loss, cognitive decline, anxiety associated with mild cognitive impairment, and other neurodegenerative and neuropsychiatric diseases, is proud to announce the appointment of David Pyrce as its new Chief Executive Officer. In conjunction with this appointment, John Mee, the current CEO, will continue his journey with Cognigenics as the President, transitioning to the role of Founder and President. Mr. Pyrce brings to the company over 30 years of biotech and pharma industry experience, together with deep Wall Street and capital markets experience, making him an invaluable addition to the Cognigenics team.
With an illustrious career that spans various facets of the healthcare and capital markets sectors, David Pyrce is recognized for his comprehensive expertise. He has served in a broad range of multifaceted roles, including as a senior investment banker, sell-side analyst and venture capitalist at Wells Fargo/Van Kasper Securities, founder, CEO and Managing General Partner of Bear Creek Capital Management, a biotech industry focused investment management firm, as well as executive positions across a diverse range of biotech and pharma companies, from early-stage startups to multinational pharmaceutical firms. Most recently, David helped create, build and grow a startup cell therapy firm from eight employees and a $350 million IPO, to over three hundred employees and a $15 billion exit.
His diverse background in investment banking, equity research, venture capital, and executive leadership roles in the biotech/pharma industry, uniquely positions him to steer Cognigenics towards new horizons of success.
“David’s appointment comes at a pivotal time for Cognigenics as we advance in our mission to revolutionize mental health treatments,” said Dr. Dean Radin, Chairman of Cognigenics. “His deep understanding of the healthcare industry, combined with his extensive experience in capital markets, aligns perfectly with our strategic goals. We are confident that under David’s leadership, Cognigenics will continue to grow and make significant strides in developing groundbreaking therapies and bringing them to market.”
Mr. Pyrce’s arrival is timely, aligning with Cognigenics’ recent achievements, including excellent preclinical results, the commencement of safety/toxicology studies and advancements in RNA-based therapies for conditions like Cognitive Impairment, Anxiety Spectrum Disorders, and Alzheimer’s Disease. His leadership is expected to propel the company’s ongoing research and development, focusing on non-invasive, long-lasting treatments that address mental health disorders with a high degree of specificity and efficacy.
“I am thrilled to join Cognigenics, a company at the forefront of genetic neuroengineering and mental health solutions,” said David Pyrce. “The potential of RNA-based therapeutics in transforming mental health care and neurodegenerative disorders is immense, and I look forward to contributing to the company’s innovative journey, driving growth, and delivering value to our stakeholders.”
Cognigenics stands committed to its ethos of pioneering effective, safe, and ethically developed treatments. With Mr. Pyrce at the helm, the company is set to continue its trajectory as a leader in cognitive health solutions, improving lives with cutting-edge genetic medicine.
